Tag: targeted therapy market analysis

Uncover key drivers, emerging technologies, and competitive movements shaping the targeted therapy market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Targeted Therapy Market expected to reach by 2030?

The targeted therapy market size has experienced significant expansion in recent years. It is anticipated to grow from $109.99 billion in 2025 to $118.16 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.4%. The observed growth in past periods can be credited to various elements, such as the increasing worldwide occurrence of cancer, the expansion of funding for oncology research, the rising adoption of monoclonal antibodies, advancements in molecular biology research, and the increasing approval of targeted cancer drugs.

The targeted therapy market is projected to experience robust expansion in the coming years. It is forecast to reach a valuation of $158.2 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.6%. This anticipated growth during the forecast period is largely driven by escalating investments in personalized medicine, the expanding application of AI-driven drug discovery, wider adoption of precision diagnostics, a growing need for less toxic cancer treatments, and heightened clinical trial activities within oncology. Key trends anticipated in this period encompass the accelerated development of precision oncology drugs, an increase in the selection of biomarker-based treatments, the broadening of combination targeted therapies, the rising utilization of companion diagnostics, and a sharpened focus on designing tumor-specific drugs.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9129&type=smp

What Drivers Are Driving Adoption Within The Targeted Therapy Market?

The rising incidence of cancer is anticipated to fuel the expansion of the targeted therapy market in the future. Cancer refers to a group of diseases characterized by abnormal cells that proliferate uncontrollably and can invade nearby tissues. Targeted therapy works by deactivating signals that promote cancer cell growth or by inducing these cells to self-destruct. This treatment uses drugs to precisely focus on the genes and proteins essential for cancer cell growth and survival, thereby boosting its demand. For example, data from the American Cancer Society, a US-based nonprofit cancer advocacy organization, indicated that in January 2024, cancer cases climbed to 2,001,140 from 1,958,310 in 2023, showing a 2.19% increase. Consequently, the growing occurrence of cancer is set to propel the targeted therapy market’s growth.

How Is The Targeted Therapy Market Organized Into Various Segments?

The targeted therapy market covered in this report is segmented –

1) By Type: Small Molecule Medicines, Monoclonal Antibodies

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Renal Cancer, Other Applications

Subsegments:

1) By Small Molecule Medicines: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors, Other Small Molecule Therapies

2) By Monoclonal Antibodies: Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), Cytokine Blockers, Other Monoclonal Antibodies

What Long-Term Trends Are Expected To Shape The Future Of The Targeted Therapy Market?

Leading companies within the targeted therapy market are prioritizing strategic alliances to ensure dependable service delivery for their customers. A strategic alliance represents an agreement between two or more companies or organizations, wherein they collaborate or support each other to achieve their mutual objectives. For instance, in September 2023, Shine Technologies, a US-based pharmaceutical firm specializing in the production of radioactive isotopes for medical applications, collaborated with Curadh MTR Inc., an entity committed to advancing and expediting the development of molecularly targeted radiation therapies for solid tumors. This collaborative effort seeks to harness the power of radioisotopes to precisely target and eradicate cancer cells, thereby offering renewed optimism to patients and redefining the trajectory of cancer treatment.

Who Are The Major Companies Operating In The Targeted Therapy Market?

Major companies operating in the targeted therapy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Genmab A/S, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Agilent Technologies Inc., Illumina Inc., Incyte Corporation, Sysmex Corporation, Exact Sciences Corporation, Seagen Inc., Exelixis Inc., Seattle Genetics Inc., Genentech Inc., Daiichi Sankyo Company Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Targeted Therapy Market?

North America was the largest region in the targeted therapy market in 2025. The regions covered in the targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Targeted Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9129&type=smp

Browse Through More Reports Similar to the Global Targeted Therapy Market 2026, By The Business Research Company

Addictions Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/addictions-therapeutics-global-market-report

Music Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/music-therapy-global-market-report

Neoantigen Targeted Therapies Market Report 2026

https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Predicted Market Size Of The Targeted Therapy Industry By 2029?

The market size for targeted therapy has exhibited robust growth in recent times. It is projected to rise from $103.84 billion in 2024 to reach $109.99 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.9%. The growth observed during the historical period is credited to improvements in molecular biology, the escalating incidence of cancer, the rising trend of personalized medicine, as well as support through FDA approvals and regulatory backing.

The market size for targeted therapy is projected to witness substantial growth in the coming years. It is set to rise to $146.89 billion in 2029, with a compound annual growth rate (CAGR) of 7.5%. This growth during the forecast period can be credited to several factors such as the expansion of oncology research, heightened demand for precision medicine, the advent of immunotherapies, increased investment in biopharmaceuticals, and improved patient awareness and advocacy. Key trends for the forecast period involve the incorporation of artificial intelligence (AI) in drug discovery, patient advocacy and increased participation in treatment choices, the growth of companion diagnostics, regulatory support for rapid approvals, and escalating investment in biotechnology and pharma.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9129&type=smp

Which Industry Forces Are Driving The Targeted Therapy Market Forward?

The surge in cancer cases is predicted to fuel the expansion of the targeted therapy market. Cancer refers to conditions characterized by abnormal cells invading surrounding tissues and multiplying without control. Targeted therapy is capable of inhibiting the growth-promoting signals of cancer cells or triggering these cells to self-destruct. This therapy uses drugs specifically designed to target genes and proteins which enable cancer cells to grow and survive, hence increasing its demand. For example, the American Cancer Society, a nonprofit organization dedicated to combating cancer in the US, reported in January 2024 that the incidence of cancer rose to 2,001,140, up from 1,958,310 in 2023, indicating a 2.19% increase. Therefore, the rising incidence of cancer is anticipated to bolster the growth of the targeted therapy market.

What Is The Segment Breakdown Of The Targeted Therapy Market?

The targeted therapymarket covered in this report is segmented –

1) By Type: Small Molecule Medicines; Monoclonal Antibodies

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By Application: Breast Cancer; Colorectal Cancer; Leukemia; Lung Cancer; Lymphoma; Renal Cancer; Other Applications

Subsegments:

1) By Small Molecule Medicines: Tyrosine Kinase Inhibitors (TKIs); Proteasome Inhibitors; Phosphatidylinositol 3-Kinase (PI3K) Inhibitors; Other Small Molecule Therapies

2) By Monoclonal Antibodies: Immune Checkpoint Inhibitors; Antibody-Drug Conjugates (ADCs); Cytokine Blockers; Other Monoclonal Antibodies

What Are The Dominant Trends Currently Seen In The Targeted Therapy Market?

Key players in the targeted therapy market are striving to introduce innovative technological solutions to consolidate their market standing. For instance, in March 2022, Novartis AG, a global pharmaceutical corporation based in Switzerland, introduced Pluvicto, having received approval from the US Food and Drug Administration (FDA). Pluvicto is the first targeted radioligand therapy (RLT) endorsed by the FDA for suitable patients with mCRPC. This therapy merges a therapeutic radioisotope with a specific chemical (a radioactive particle), making it a unique targeted cancer treatment. Pluvicto specifically binds to cells in the bloodstream, including prostate cancer cells which express the PSMA transmembrane protein. Once attached, the radioisotope’s energy emissions damage the targeted cells and nearby cells, obstructing cell replication and/or causing cell death.

Which Companies Are Contributing Significantly To The Targeted Therapy Market Growth?

Major companies operating in the targeted therapy market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Genmab A/S, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Agilent Technologies Inc., Illumina Inc., Incyte Corporation, Sysmex Corporation, Exact Sciences Corporation, Seagen Inc., Exelixis Inc., Seattle Genetics Inc., Genentech Inc., Daiichi Sankyo Company Limited

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Which Region Is Leading Innovation In The Targeted Therapy Market?

North America was the largest region in the targeted therapy market in 2024. The regions covered in the targeted therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=9129&type=smp

Browse Through More Reports Similar to the Global Targeted Therapy Market 2025, By The Business Research Company

Cells Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Cell Culture Consumables And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Cell Based Assays Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Targeted Therapy Industry In 2025?

The targeted therapy market size has experienced significant growth in recent years. This market is set to expand from $103.84 billion in 2024 to $109.99 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.9%. The past growth within this sector can be attributed to developments in molecular biology, a rising incidence of cancer, the shift towards personalized medicine, and crucial FDA approvals along with regulatory assistance.

The targeted therapy market size is anticipated to demonstrate robust expansion over the next few years. It is projected to increase to $146.89 billion by 2029, achieving a compound annual growth rate (CAGR) of 7.5%. The expansion during this forecast period can be ascribed to several factors, including the growth in oncology research, an increasing demand for precision medicine, the emergence of immunotherapies, rising investment in biopharmaceuticals, and enhanced patient awareness and advocacy. Significant trends expected in the forecast period encompass the incorporation of artificial intelligence (AI) into drug discovery, greater patient advocacy and involvement in treatment decisions, the broadening of companion diagnostics, regulatory backing for accelerated approvals, and increased investment in the biotechnology and pharmaceutical industries.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9129&type=smp

Which Drivers Are Impacting The Targeted Therapy Market?

The expanding incidence of cancer is projected to stimulate the growth of the targeted therapy market. Cancer refers to conditions characterized by the uncontrolled division of abnormal cells that can infiltrate surrounding tissues. Targeted therapy functions by deactivating signals that promote the proliferation of cancerous cells or by inducing these cells to self-destruct. It utilizes specific medications to pinpoint genes and proteins essential for the growth and survival of cancer cells, thereby escalating its demand. For instance, data from January 2024, provided by the American Cancer Society, a US-based nonprofit cancer advocacy organization, revealed that cancer cases climbed to 2,001,140 compared to 1,958,310 in 2023, representing a growth of 2.19%. Consequently, the rising prevalence of cancer will serve as a key driver for the targeted therapy market.

What Are The Key Segments In The Targeted Therapy Market?

The targeted therapymarket covered in this report is segmented –

1) By Type: Small Molecule Medicines; Monoclonal Antibodies

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By Application: Breast Cancer; Colorectal Cancer; Leukemia; Lung Cancer; Lymphoma; Renal Cancer; Other Applications

Subsegments:

1) By Small Molecule Medicines: Tyrosine Kinase Inhibitors (TKIs); Proteasome Inhibitors; Phosphatidylinositol 3-Kinase (PI3K) Inhibitors; Other Small Molecule Therapies

2) By Monoclonal Antibodies: Immune Checkpoint Inhibitors; Antibody-Drug Conjugates (ADCs); Cytokine Blockers; Other Monoclonal Antibodies

What Are The Major Trends Driving The Growth Of The Targeted Therapy Market?

Major companies in the targeted therapy market are actively developing novel technological solutions to reinforce their market presence. For example, in March 2022, Novartis AG, a multinational pharmaceutical corporation based in Switzerland, launched Pluvicto following its approval by the US Food and Drug Administration (FDA). Pluvicto is the inaugural FDA-approved targeted radioligand therapy (RLT) for qualifying patients with mCRPC. This targeted cancer therapy combines a therapeutic radioisotope with a specific chemical (a radioactive particle). Pluvicto attaches to target cells circulating in the body, including prostate cancer cells that express the transmembrane protein PSMA. Once bound, the radioisotope’s emitted energy damages the target cells and other cells in the vicinity, preventing their replication and/or initiating cell death.

Who Are The Core Companies Influencing The Targeted Therapy Market Landscape?

Major companies operating in the targeted therapy market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Genmab A/S, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Agilent Technologies Inc., Illumina Inc., Incyte Corporation, Sysmex Corporation, Exact Sciences Corporation, Seagen Inc., Exelixis Inc., Seattle Genetics Inc., Genentech Inc., Daiichi Sankyo Company Limited

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Targeted Therapy Market?

North America was the largest region in the targeted therapy market in 2024. The regions covered in the targeted therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Targeted Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9129&type=smp

Browse Through More Reports Similar to the Global Targeted Therapy Market 2025, By The Business Research Company

Cells Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Cell Culture Consumables And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Cell Based Assays Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Targeted Therapy Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In recent times, the targeted therapy market has seen robust growth. The market size is projected to increase from $103.84 billion in 2024 to $109.99 billion in 2025, with a compound annual growth rate (CAGR) of 5.9%. Factors that contributed to this growth during the historical period include developments in molecular biology, a rise in cancer cases, the popularity of personalized medicine, the approval of the FDA, and regulatory assistance.

The market for targeted therapy is set to experience significant expansion in the coming years. It is predicted to reach a worth of $146.89 billion in 2029, with a compound annual growth rate of 7.5%. The predicted growth during this period is driven by a range of factors including increasing oncology research, the rising need for precision medicine, the advent of immunotherapies, augmented investments in biopharmaceuticals, patient awareness, and advocacy. The forecast period will see trends such as the incorporation of artificial intelligence in drug discovery, patient advocacy and participation in treatment decisions, the growth of companion diagnostics, regulatory support for accelerated approvals, and an increase in investment in biotechnology and pharma.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9129&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theTargeted Therapy Market?

The surge in cancer incidence is predicted to boost the advancement of the targeted therapy market. The term cancer refers to disorders where abnormal cells can uncontrollably multiply and infect nearby tissues. By utilising drugs that specifically target proteins and genes instrumental for the growth and survival of cancerous cells, targeted therapy can inhibit cancer cell proliferation or prompt these cells to self-destruct, thus increasing its demand. To illustrate, the American Cancer Society, a non-profit cancer advocacy organization based in the U.S., reported in January 2024 that the number of cancer cases grew from 1,958,310 in 2023 to 2,001,140, indicating a 2.19% growth. Therefore, the rising incidence of cancer is expected to fuel the growth of the targeted therapy market.

Which Segments in the Targeted Therapy Offer the Most Growth?

The targeted therapymarket covered in this report is segmented –

1) By Type: Small Molecule Medicines; Monoclonal Antibodies

2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3) By Application: Breast Cancer; Colorectal Cancer; Leukemia; Lung Cancer; Lymphoma; Renal Cancer; Other Applications

Subsegments:

1) By Small Molecule Medicines: Tyrosine Kinase Inhibitors (TKIs); Proteasome Inhibitors; Phosphatidylinositol 3-Kinase (PI3K) Inhibitors; Other Small Molecule Therapies

2) By Monoclonal Antibodies: Immune Checkpoint Inhibitors; Antibody-Drug Conjugates (ADCs); Cytokine Blockers; Other Monoclonal Antibodies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=9129&type=smp

What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theTargeted Therapy Market?# Market?

North America was the largest region in the targeted therapy market in 2024. The regions covered in the targeted therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Targeted Therapy Industry?

Leading entities in the targeted therapy market are prioritizing the creation of novel technological solutions to solidify their market standing. For instance, Novartis AG, a renowned pharmaceutical corporation headquartered in Switzerland, introduced Pluvicto in March 2022, a product that received approval from the US Food and Drug Administration (FDA). Pluvicto is distinguished as the first FDA-sanctioned targeted radioligand therapy (RLT) intended for suitable patients diagnosed with mCRPC. This innovative therapy fuses a healing radioisotope with a specifically targeted chemical (a radioactive particle). Pluvicto is a form of targeted cancer treatment that pairs a therapeutic radioisotope with a specific targeting chemical. When attached, Pluvicto targets cells in the circulation like prostate cancer cells expressing the PSMA transmembrane protein. Once bonded, energy emissions from the radioisotope damage the target cells and other neighbouring cells, inhibiting their ability to replicate and in some instances, causing cell death.

View the full report here:

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

What Are the Key Elements That Define the Targeted Therapy Market?

Targeted therapy refers to a kind of cancer treatment that employs medications or other chemicals to attack particular molecules required for the survival and spread of cancer cells. It uses drugs to target specific genes and proteins that help cancer cells survive and grow.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9129

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Targeted Therapy Market Size Changed, over the years?

The market size of targeted therapy has significantly increased in the past few years. The market, which was valued at $103.84 billion in 2024, is projected to expand to $111.47 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.3%. Innovations in molecular biology, the rising prevalence of cancer, the personalization of medicine, endorsements from the FDA, and a supportive regulatory environment are all contributing factors to this historic growth period.

How Much Will the Targeted Therapy Market Be Worth in 2029?

The targeted therapy market is projected to experience significant growth in the approaching years. The market is estimated to reach a value of $151.48 billion in 2029, with a compound annual growth rate (CAGR) of 8.0%. This market expansion in the forecast period is due to the growth in oncology research, an increase in demand for precision medicine, the advent of immunotherapies, increased funding in biopharmaceuticals, along with patient enlightenment and advocacy. Key trends for the forecast period include the application of artificial intelligence (AI) in drug innovation, patient advocacy influencing treatment choices, the growth of companion diagnostics, regulatory support favoring rapid approvals, and amplified investment in the biotechnology and pharmaceutical sectors.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9129&type=smp

Which is the Largest Company in the Targeted Therapy Market?

Major companies operating in the targeted therapy market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Genmab A/S, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Agilent Technologies Inc., Illumina Inc., Incyte Corporation, Sysmex Corporation, Exact Sciences Corporation, Seagen Inc., Exelixis Inc., Seattle Genetics Inc., Genentech Inc., Daiichi Sankyo Company Limited

What Are the Main Market Drivers in the Targeted Therapy Industry?

The rising incidence of cancer is anticipated to stimulate the advancement of the targeted therapy market. Cancer refers to conditions in which abnormal cells can multiply uncontrollably and harm surrounding tissues. Targeted therapy has the ability to counteract the signals that catalyze the proliferation of cancer cells or induce self-destruction in cancer cells. The drugs used in this therapeutic strategy specifically aim at genes and proteins facilitating the growth and survival of cancer cells, thereby amplifying its demand. For example, the American Cancer Society, a nonprofit cancer advocacy organization based in the US, reported that the cancer cases escalated to 2,001,140 in January 2024 as compared to 1,958,310 in 2023, marking a surge of 2.19%. As a result, the escalating cancer prevalence will be a pivotal driving force for the targeted therapy market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9129&type=smp

How Is the Targeted Therapy Market Segments Structured?

The targeted therapy market covered in this report is segmented –

1) By Type: Small Molecule Medicines, Monoclonal Antibodies

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Renal Cancer, Other Applications

Subsegments:

1) By Small Molecule Medicines: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors, Other Small Molecule Therapies

2) By Monoclonal Antibodies: Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), Cytokine Blockers, Other Monoclonal Antibodies

What Strategic Trends Are Transforming the Targeted Therapy Market?

Key players within the targeted therapy sector are striving to advance new technological solutions to consolidate their market presence. For instance, a major Switzerland-based multinational pharmaceutical corporation, Novartis AG, introduced Pluvicto in March 2022, having received approval from the US Food and Drug Administration (FDA). This is the first FDA-sanctioned targeted radioligand therapy (RLT) for qualified patients suffering from mCRPC. Pluvicto merges a therapeutic radioisotope with a targeted chemical, also known as a radioactive particle, forming a unique type of targeted cancer therapy. Pluvicto attaches to target cells in the bloodstream, such as prostate cancer cells that express the transmembrane protein PSMA. Upon attachment, the energy emissions from the radioisotope damage these target cells along with nearby cells, thereby preventing replication and/or inducing cell death.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Which Global Regions Offer the Highest Growth in the Targeted Therapy Market?

North America was the largest region in the targeted therapy market in 2024. The regions covered in the targeted therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9129

This Report Delivers Insight On:

1. How big is the targeted therapy market, and how is it changing globally?

2. Who are the major companies in the targeted therapy market, and how are they performing?

3. What are the key opportunities and risks in the targeted therapy market right now?

4. Which products or customer segments are growing the most in the targeted therapy market?

5. What factors are helping or slowing down the growth of the targeted therapy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the targeted therapy industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#How Has The Targeted Therapy Market Size Shifted, And What Is the Outlook Through 2034?#_x000D_

The market size of targeted therapy has seen a solid expansion in the past few years. It is projected to escalate from $103.84 billion in 2024 to an impressive $111.47 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.3%. Factors such as progress in molecular biology, rising cancer rates, the shift towards personalized medicine, FDA certifications, and regulatory backing fueled the growth during the historic period._x000D_

_x000D_

The market size for targeted therapy is anticipated to experience robust growth in the approaching years. The market is predicted to expand to $151.48 billion in 2029, with a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this projected growth during the forecast period include the expansion of oncology research, the surging need for precision medicine, the emergence of immunotherapies, escalating investment in biopharmaceuticals, and increased patient awareness and advocacy. Key trends to watch during the forecast period include the integration of artificial intelligence (AI) into drug discovery, increased patient advocacy and involvement in treatment decisions, the growth of companion diagnostics, regulatory backing for accelerated approvals, as well as rising investment in biotechnology and pharmaceuticals._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=9129&type=smp_x000D_

_x000D_

#What Are the Core Market Drivers Propelling Growth in the Targeted Therapy Industry?#_x000D_

The surge in cancer incidents is predicted to stimulate the expansion of the targeted therapy market in the future. Cancer refers to diseases where abnormal cells can proliferate uncontrollably and invade neighboring tissues. Targeted therapy can hinder the triggers that stimulate the multiplication of cancer cells or instruct the cancer cells to eliminate themselves. This treatment uses drugs that specifically aim at the genes and proteins which facilitate the expansion and survival of cancer cells, thereby heightening its demand. For example, the American Cancer Society, a nonprofit cancer advocacy organization based in the US, reported in January 2024 that the cancer cases escalated to 2,001,140 from 1,958,310 in 2023, suggesting a growth rate of 2.19%. Hence, the escalating occurrence of cancer will fuel the advancement of the targeted therapy market._x000D_

_x000D_

#How Is the Targeted Therapy Market Segmented?#_x000D_

The targeted therapy market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Small Molecule Medicines, Monoclonal Antibodies_x000D_

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_

3) By Application: Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Renal Cancer, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By Small Molecule Medicines: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors, Other Small Molecule Therapies_x000D_

2) By Monoclonal Antibodies: Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), Cytokine Blockers, Other Monoclonal Antibodies_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=9129&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Targeted Therapy Market Growth?#_x000D_

North America was the largest region in the targeted therapy market in 2024. The regions covered in the targeted therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Market Trends and Innovations Are Shaping the Future of the Targeted Therapy Industry?#_x000D_

In an effort to solidify their dominance in the targeted therapy market, leading corporations are investing in the creation of innovative technological solutions. In March 2022, for instance, the multinational pharmaceutical corporation based in Switzerland, Novartis AG, introduced Pluvicto, a product that received approval from the US Food and Drug Administration (FDA). Notably, Pluvicto marks the first FDA-sanctioned targeted radioligand therapy (RLT) for selected patients suffering from mCRPC. It fuses a therapeutic radioisotope with a specific chemical (a radioactive particle), originating a variant of targeted cancer therapy which merges a therapeutic radioisotope and a targeted chemical. By adhering to circulating target cells including those of prostate cancer expressing the PSMA transmembrane protein, Pluvicto ensures that the radioisotope’s energy emissions harm these cells and others nearby, restricting replication and potentially causing cell death._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report_x000D_

_x000D_

#How Is the Targeted Therapy Market Defined and What Are Its Core Parameters?#_x000D_

Targeted therapy refers to a kind of cancer treatment that employs medications or other chemicals to attack particular molecules required for the survival and spread of cancer cells. It uses drugs to target specific genes and proteins that help cancer cells survive and grow._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9129_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model